Legal & General Group Plc Takes Position in Sarepta Therapeutics, Inc. $SRPT

Key Points

• Legal & General Group Plc acquired 877,627 Sarepta Therapeutics shares worth approximately $15.8 million in the second quarter, giving it a 0.83% stake. Institutional investors and hedge funds collectively own 86.68% of SRPT.
• Analyst sentiment is mixed: nine analysts rate SRPT a Buy, six a Hold, and five a Sell. MarketBeat reports an overall “Hold” rating with an average price target of $25.06.
• Sarepta beat quarterly expectations with adjusted EPS of $0.64 versus a $0.22 consensus and revenue of $401.25 million, but revenue declined 34.3% year over year and the company reported a negative net margin.

Legal & General Group Plc acquired a new position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 877,627 shares of the biotechnology company's stock, valued at approximately $15,771,000. Legal & General Group Plc owned approximately 0.83% of Sarepta Therapeutics as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in SRPT. Kestra Advisory Services LLC acquired a new stake in Sarepta Therapeutics in the 4th quarter valued at $25,000. iSAM Funds UK Ltd acquired a new position in shares of Sarepta Therapeutics during the 3rd quarter worth about $25,000. Meeder Asset Management Inc. bought a new position in shares of Sarepta Therapeutics in the 2nd quarter valued at about $27,000. Ancora Advisors LLC grew its holdings in shares of Sarepta Therapeutics by 200.0% in the 3rd quarter. Ancora Advisors LLC now owns 1,500 shares of the biotechnology company's stock valued at $29,000 after acquiring an additional 1,000 shares in the last quarter. Finally, Allworth Financial LP increased its position in shares of Sarepta Therapeutics by 2,098.8% in the third quarter. Allworth Financial LP now owns 1,803 shares of the biotechnology company's stock valued at $35,000 after acquiring an additional 1,721 shares during the last quarter. Institutional investors and hedge funds own 86.68% of the company's stock.

Analysts Set New Price Targets

A number of research analysts have weighed in on SRPT shares. Piper Sandler decreased their price target on Sarepta Therapeutics from $23.00 to $20.00 and set a "neutral" rating for the company in a research note on Thursday, July 9th. Weiss Ratings cut Sarepta Therapeutics from a "sell (d)" rating to a "sell (e+)" rating in a research note on Wednesday, August 19th. HC Wainwright reissued a "buy" rating on shares of Sarepta Therapeutics in a report on Tuesday, July 28th. Zacks Research raised shares of Sarepta Therapeutics from a "strong sell" rating to a "hold" rating in a research note on Wednesday, August 12th. Finally, Wolfe Research upgraded shares of Sarepta Therapeutics from a "peer perform" rating to an "outperform" rating and set a $27.00 target price on the stock in a report on Thursday, July 9th. Nine analysts have rated the stock with a Buy rating, six have given a Hold rating and five have issued a Sell rating to the company. According to MarketBeat, Sarepta Therapeutics has an average rating of "Hold" and an average price target of $25.06.

Sarepta Therapeutics Stock Performance

Sarepta Therapeutics stock opened at $20.86 on Monday. The stock has a 50-day simple moving average of $17.73 and a 200 day simple moving average of $18.32. The stock has a market capitalization of $2.20 billion, a P/E ratio of -7.19, a PEG ratio of 0.31 and a beta of 0.24. The company has a debt-to-equity ratio of 0.55, a quick ratio of 2.62 and a current ratio of 4.42. Sarepta Therapeutics, Inc. has a 52 week low of $14.68 and a 52 week high of $25.32.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last released its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $0.64 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.22 by $0.42. Sarepta Therapeutics had a negative return on equity of 1.60% and a negative net margin of 13.48%.The firm had revenue of $401.25 million for the quarter, compared to analyst estimates of $366.39 million. During the same quarter in the prior year, the company earned $2.02 earnings per share. The business's revenue for the quarter was down 34.3% compared to the same quarter last year. Analysts expect that Sarepta Therapeutics, Inc. will post 3.43 earnings per share for the current year.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta's core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company's mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta's commercial products include several exon-skipping therapies approved by the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source